person · Reporting owner
Cooper Laurence James Neil
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director · President and CEO | January 04, 2021 | January 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date January 04, 2021 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,799,280 |
Reported balance
After 2021-01-04 transaction · row 1
1 source rowRow 1 · 2021-01-04 · Sale · Disposed 105,693 · Balance 1,799,280 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 6, 2021 22:02 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 105,693 | $2.71 | $286,428.03 |
DisclosureSEC source: 0001209191-21-002171 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799,280 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:45 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 264,200 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005780 · doc4.xml · derivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,200 Underlying: Common Stock · 264,200 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:45 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 171,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005780 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,904,973 F1 · shares: 57,234 shares shall vest on 12/31/2020 and 57,233 shares shall vest on each of 12/31/2021 and 12/31/2022. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 21:37 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 110,694 | $4.88 | $540,186.72 |
DisclosureSEC source: 0001209191-19-062290 · doc4.xml · nonDerivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:37 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 44,642 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-062290 · doc4.xml · derivative · entry 3 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,171 Underlying: Common Stock · 44,642 shares Expires 2029-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:37 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionCommon Stock | 44,642 | $2.24 | $99,998.08 |
DisclosureSEC source: 0001209191-19-062290 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,843,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 531,813 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · derivative · entry 4 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,813 Underlying: Common Stock · 531,813 shares Expires 2029-01-06 F4 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 165,178 | $2.24 | $369,998.72 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · nonDerivative · entry 3 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799,325 F3 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grant. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 446,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · nonDerivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964,503 F2 · shares: Pursuant to the Issuer's option plan, the Reporting Person elected to receive fully vested shares of Common Stock in lieu of a cash bonus. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:24 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 337,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002778 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518,075 F1 · shares: 112,422 shares shall vest on each of 12/31/2019, 12/31/2020 and 12/31/2021. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:15 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 16,156 | $1.87 | $30,211.72 |
DisclosureSEC source: 0001209191-19-000586 · doc4.xml · nonDerivative · entry 3 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,180,809 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2018 Filed Jan 3, 2019 02:15 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 26,178 | $1.66 | $43,455.48 |
DisclosureSEC source: 0001209191-19-000586 · doc4.xml · nonDerivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,196,965 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 29, 2018 Filed Jan 3, 2019 02:15 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 42,920 | $1.66 | $71,247.20 |
DisclosureSEC source: 0001209191-19-000586 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223,143 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| May 05, 2018 Filed May 24, 2018 21:11 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 123,333 | $4.41 | $543,898.53 |
DisclosureSEC source: 0001209191-18-033067 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,266,063 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:54 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 16,157 | $4.14 | $66,889.98 |
DisclosureSEC source: 0001209191-18-000993 · doc4.xml · nonDerivative · entry 3 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,389,396 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 21:54 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 26,178 | $4.14 | $108,376.92 |
DisclosureSEC source: 0001209191-18-000993 · doc4.xml · nonDerivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405,553 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:54 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 348,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-000993 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,431,731 F1 · shares: 116,000 shares shall vest on each of 12/29/2018, 12/29/2019 and 12/29/2020. Read SEC document |
| November 08, 2017 Filed Nov 9, 2017 21:43 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 6,440 | $4.68 | $30,139.20 |
DisclosureSEC source: 0001209191-17-059988 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,083,731 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.66 to $4.71, inclusive.The Reporting Person undertakes to provide to the Issuer, any stockholder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 05, 2017 Filed May 9, 2017 22:50 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 132,000 | $7.12 | $939,840.00 |
DisclosureSEC source: 0001209191-17-031086 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,291 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:41 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 17,292 | $5.35 | $92,512.20 |
DisclosureSEC source: 0001209191-17-000996 · doc4.xml · nonDerivative · entry 2 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,209,291 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:41 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 212,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-000996 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,226,583 F1 · shares: 70,750 shares vest on each of 12/30/2017, 12/30/2018 and 12/30/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.